Cytogen, Inc. (KOSDAQ:217330)
South Korea
· Delayed Price · Currency is KRW 3,825.00
+15.00 (0.39%)
At close: Mar 28, 2025, 3:30 PM KST
Cytogen Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Net Income | -17,117 | -15,770 | -18,771 | -10,871 |
| Depreciation & Amortization | 2,088 | 1,912 | 1,314 | 1,114 |
| Loss (Gain) From Sale of Assets | 0 | 79.33 | 0 | 0 |
| Asset Writedown & Restructuring Costs | 3,486 | 3,164 | - | - |
| Loss (Gain) From Sale of Investments | 2,896 | 1,412 | -139.47 | -472.78 |
| Stock-Based Compensation | 568.38 | 1,866 | 2,806 | 5,453 |
| Provision & Write-off of Bad Debts | 179.58 | 153.49 | 2.88 | - |
| Other Operating Activities | 1,265 | 96.49 | 8,785 | -493.66 |
| Change in Accounts Receivable | -2,444 | -11.91 | -235.79 | 473.7 |
| Change in Inventory | -1,488 | 33.25 | -131.47 | - |
| Change in Accounts Payable | 1,566 | 17.14 | 35.37 | 45.54 |
| Change in Other Net Operating Assets | -530.74 | -545.32 | -43.44 | -479.02 |
| Operating Cash Flow | -9,529 | -7,594 | -6,379 | -5,230 |
| Capital Expenditures | -1,007 | -2,498 | -645.8 | -1,219 |
| Sale of Property, Plant & Equipment | 1.32 | 78.94 | - | 0.76 |
| Cash Acquisitions | -13,184 | - | -9,561 | - |
| Sale (Purchase) of Intangibles | -117.27 | 175.58 | -99.24 | -777.85 |
| Investment in Securities | -9,857 | 2,385 | 3,592 | -4,030 |
| Other Investing Activities | -185.71 | 121.52 | 60.59 | 140.93 |
| Investing Cash Flow | -24,349 | 263.39 | -6,654 | -5,585 |
| Short-Term Debt Issued | - | 3,083 | - | - |
| Long-Term Debt Issued | 9,800 | 17,934 | - | 30,000 |
| Total Debt Issued | 9,800 | 21,017 | - | 30,000 |
| Short-Term Debt Repaid | -905.16 | -2,571 | - | - |
| Long-Term Debt Repaid | -6,251 | -11,840 | -493.12 | -426.55 |
| Total Debt Repaid | -7,156 | -14,411 | -493.12 | -426.55 |
| Net Debt Issued (Repaid) | 2,644 | 6,606 | -493.12 | 29,573 |
| Issuance of Common Stock | 6,500 | 40,000 | 1,119 | 409.95 |
| Other Financing Activities | 28.05 | -369.5 | -1,665 | 43.29 |
| Financing Cash Flow | 9,172 | 46,236 | -1,039 | 30,027 |
| Foreign Exchange Rate Adjustments | -17.33 | 53.61 | -338.4 | - |
| Miscellaneous Cash Flow Adjustments | -0 | - | - | -0 |
| Net Cash Flow | -24,724 | 38,960 | -14,410 | 19,212 |
| Free Cash Flow | -10,536 | -10,092 | -7,024 | -6,449 |
| Free Cash Flow Margin | -96.56% | -316.91% | -923.33% | -1853.87% |
| Free Cash Flow Per Share | -466.56 | -551.63 | -397.69 | -380.57 |
| Cash Interest Paid | 33.71 | 16.8 | - | - |
| Cash Income Tax Paid | 187.12 | -44.57 | 21.79 | -23.61 |
| Levered Free Cash Flow | -11,340 | -13,734 | 4,146 | - |
| Unlevered Free Cash Flow | -10,033 | -11,836 | 6,599 | - |
| Change in Net Working Capital | 4,437 | 5,135 | -10,948 | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.